Koh Mariko Siyue, Lam Sean Shao Wei, Xu Xiaomeng, Wu Jun Tian, Ratnasingham Priyan, Marsel Ricco, Ong Marcus Eng Hock, Matchar David Bruce, Tan Ngiap Chuan, Loo Chian Min
Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, Singapore.
Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
Pragmat Obs Res. 2024 Dec 7;15:209-220. doi: 10.2147/POR.S477225. eCollection 2024.
Patients with asthma in Singapore often have complex patient journeys, with diagnosis and management across various primary and speciality care settings. Real-world population health data is needed to identify care gaps and inform policies.
This retrospective, longitudinal cohort study assessed real-world data from adults (aged ≥18 years) with asthma in the SingHealth Chronic Obstructive Pulmonary Disease and Asthma Data Mart, an integrated database of electronic medical records of patients who attended primary and/or speciality care clinics in the SingHealth Regional Health System 01/01/2015-12/31/2020. Patients were indexed by first asthma diagnosis and categorized into cohorts of index year. Patient characteristics, asthma management and outcomes were described during baseline (1-year pre-index) and follow-up periods (1-year post-index).
Overall, 21,215 patients were included across 4 cohorts: 2016, N=12,947; 2017, N=3419; 2018, N=2816; 2019, N=2033. Most common baseline asthma medication changed from inhaled corticosteroids (ICS) alone in the 2016 cohort (32.8% [n=4252]) to ICS/long-acting β-agonist in the 2019 cohort (33.3% [n=677]). Asthma symptom control (mean [SD] Asthma Control Test scores) improved from 2016 to 2019 during baseline (18.38 [4.93] vs 19.87 [4.56]; <0.001) and follow-up (18.34 [4.23] vs 21.07 [3.51]; <0.001). Mean (standard deviation [SD]) number of exacerbations per patient during follow-up decreased from 2016 to 2019 (1.91 [3.11] vs 0.89 [2.07]; <0.001). Mean (SD) number of emergency department visits per patient during follow-up decreased from 0.21 (0.75) in 2016 to 0.17-0.18 (0.60-0.65; <0.001) between 2017 and 2019.
Health status at first asthma diagnosis improved for each succeeding cohort from 2016 to 2019, along with improvements in patient management and outcomes. This reflects greater awareness of the condition and improved use of medication and referrals in recent years, suggesting policy changes and their implementation, including promotion of disease awareness and adoption of guideline recommendations, may improve asthma outcomes in Singapore.
新加坡哮喘患者的就医过程往往较为复杂,涉及在不同的基层医疗和专科医疗环境中进行诊断和管理。需要真实世界的人群健康数据来识别医疗差距并为政策提供依据。
这项回顾性纵向队列研究评估了新加坡健康集团慢性阻塞性肺疾病和哮喘数据中心中成年哮喘患者(年龄≥18岁)的真实世界数据,该数据中心是新加坡健康集团区域卫生系统中2015年1月1日至2020年12月31日期间就诊于基层和/或专科诊所的患者电子病历综合数据库。患者以首次哮喘诊断为索引,并按索引年份分为不同队列。在基线期(索引前1年)和随访期(索引后1年)描述了患者特征、哮喘管理情况及结局。
总体而言,4个队列共纳入21215例患者:2016年队列,N = 12947例;2017年队列,N = 3419例;2018年队列,N = 2816例;2019年队列,N = 2033例。最常用的基线哮喘药物从2016年队列中单独使用吸入性糖皮质激素(ICS)(32.8% [n = 4252])变为2019年队列中使用ICS/长效β受体激动剂(33.3% [n = 677])。从2016年到2019年,基线期(18.38 [4.93] 对 19.87 [4.56];<0.001)和随访期(18.34 [4.23] 对 21.07 [3.51];<0.001)哮喘症状控制(平均 [标准差] 哮喘控制测试得分)得到改善。随访期间每位患者的平均(标准差 [SD])急性加重次数从2016年到2019年减少(1.91 [3.11] 对 0.89 [2.07];<0.001)。随访期间每位患者的平均(SD)急诊就诊次数从2016年的0.21(0.75)降至2017年至2019年期间的0.17 - 0.18(0.60 - 0.65;<0.001)。
从队列研究结果来看,2016年至2019年,每一个后续队列在首次哮喘诊断时的健康状况都有所改善,同时患者管理和结局也有所改善。这反映出近年来对该疾病的认识有所提高,药物使用和转诊情况得到改善,表明政策变化及其实施,包括提高疾病认知度和采用指南建议,可能会改善新加坡哮喘患者的结局。